Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ciclesonide
Drug ID BADD_D00460
Description Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Indications and Usage For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
Marketing Status approved; investigational
ATC Code R01AD13; R03BA08
DrugBank ID DB01410
KEGG ID D01703
MeSH ID C120481
PubChem ID 6918155
TTD Drug ID D0K7HU
NDC Product Code 70515-711; 53104-7633; 70515-712; 70515-701; 64918-1900; 24002-0016; 64918-1112; 70515-737
UNII S59502J185
Synonyms ciclesonide | (R)-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate | Alvesco | Omnaris
Chemical Information
Molecular Formula C32H44O7
CAS Registry Number 126544-47-6
SMILES CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nausea07.01.07.0010.000947%
Night sweats08.01.03.031; 23.02.03.006---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.0110.000379%
Oral candidiasis07.05.07.001; 11.03.03.004---
Osteoporosis14.04.04.002; 15.02.03.002--
Pain in extremity15.03.04.010--
Palpitations02.11.04.012--
Paraesthesia17.02.06.005; 23.03.03.094--
Personality change17.02.05.019; 19.05.01.006--
Pharyngeal oedema10.01.05.016; 22.04.05.003; 23.04.01.016---
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Pharyngitis streptococcal11.02.06.002; 22.07.04.001---
Pleural effusion22.05.02.0020.000379%
Pneumonia11.01.09.003; 22.07.01.003---
Presyncope02.11.04.013; 17.02.05.009; 24.06.02.010--
Productive cough22.02.03.005--
Pruritus23.03.12.0010.001137%
Pulmonary congestion02.05.02.002; 22.01.03.002; 24.03.08.001---
Pulmonary embolism22.06.02.001; 24.01.06.0010.000379%-
Pulmonary fibrosis22.01.02.0060.000379%
Pyrexia08.05.02.0030.000568%
Rales22.12.01.011---
Rash23.03.13.0010.000568%-
Rash papular23.03.13.017---
Respiratory disorder22.02.07.0020.000568%-
Respiratory failure14.01.04.003; 22.02.06.0020.000379%
Rhinitis11.01.13.004; 22.07.03.006--
Rhinitis allergic10.01.04.003; 22.04.04.003--
Rhinorrhoea22.12.03.021--
Secondary adrenocortical insufficiency05.03.04.012; 14.11.01.014---
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages